105772-13-2

Usage

Uses

Used in Pharmaceutical Industry:
3,6-Dihydro-2H-pyran-4-carbonitrile is utilized as a key intermediate in the synthesis of new drugs and biologically active compounds. Its structural features allow for the development of molecules with potential therapeutic applications, making it a valuable asset in drug discovery and medicinal chemistry research.
Used in Antimicrobial Applications:
3,6-Dihydro-2H-pyran-4-carbonitrile has demonstrated antimicrobial properties, positioning it as a candidate for the treatment of bacterial infections. Its ability to inhibit the growth of various microorganisms could lead to the creation of new antimicrobial agents to combat resistant strains and address the growing need for novel antibiotics.
Used in Antifungal Applications:
3,6-Dihydro-2H-pyran-4-carbonitrile also exhibits antifungal activity, making it a promising agent for the treatment of fungal infections. Its potential to target and eliminate fungi could contribute to the development of new antifungal drugs, addressing the need for effective treatments against a range of fungal pathogens.

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 773837-37-9 sodium cyanide 
• 50289-10-6 4-hydroxy-tetrahydropyran-4-carbonitrile 
• 7677-24-9 trimethylsilyl cyanide 

Relevant academic research and scientific papers

The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties

The discovery of a potent selective low dose Janus kinase 1 (JAK1) inhibitor suitable for clinical evaluation is described. As part of an overall goal to minimize dose, we pursued a medicinal chemistry strategy focused on optimization of key parameters th

PROCESS FOR PREPARING 1-[(3R,4S)-4-CYANOTETRAHYDROPYRAN-3-YL]-3-[(2-FLUORO-6-METHOXY-4-PYRIDYL)AMINO]P YRAZOLE-4-CARBOXAMIDE

The application relates to processes for the preparation of 1-[(3R,4S) -4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl) amino]pyrazole-4-carboxamide (I) which include (i) a synthesis for bromo and iodo pyridine intermediates, (ii) a synthesis of a pyrazole ester intermediate which can be obtained in enantiopure form and (iii) the combination of these intermediates into compound (I).

FACTOR XIIA INHIBITORS

This invention relates to compoundsof formula (I)and methods of treatment using the compounds. The invention also relates to processes and methods for producing the compounds of the invention. The compounds of the invention are modulators of Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.

AMINOPYRAZOLES AS SELECTIVE JANUS KINASE INHIBITORS

The instant invention provides compounds of formula I which are selective JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as atopic dermatitis, arthritis, and cancer.

AMINOPYRAZOLES AS JANUS KINASE INHIBITORS

The instant invention provides compounds which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

N-(2-CYANO HETEROCYCLYL)PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS

Provided are compounds of Formula I, a JAK inhibitor, and use thereof for the treatment of JAK-mediated diseases by the application.

Facile entry to an efficient and practical enantioselective synthesis of a polycyclic cholesteryl ester transfer protein inhibitor

An efficient enantioselective synthesis of the chiral polycyclic cholesteryl ester transfer protein (CETP) inhibitor 1 has been developed. The synthesis was rendered practical for large scale via the development of a modified Hantzsch-type reaction to prepare the sterically hindered pyridine ring, enantioselective hydrogenation of hindered ketone 6 utilizing novel BIBOP-amino-pyridine derived Ru complex, efficient ICl promoted lactone formation, and a BF3 mediated hydrogenation process for diastereoselective lactol reduction. This efficient route was successfully scaled to produce multikilogram quantities of challenging CETP drug candidate 1.

Highly enantioselective quinoline synthesis via ene-type cyclization of 1,7-enynes catalyzed by a cationic BINAP-palladium(II) complex

The first highly enantioselective synthesis of a six-membered ring quinoline catalyzed by a cationic BINAP-palladium(II) complex is shown to afford the quinoline products having a quaternary carbon center or a spiro-ring in quantitative yield and >99% ee.